Xencor INC 8-K filings

Xencor announced its first quarter 2024 financial results, highlighting progress in its clinical programs and the approval of Ultomiris for NMOSD.

Xencor, a clinical-stage biopharmaceutical company, has appointed Bart Cornelissen as its new Senior Vice President and Chief Financial Officer, effective April 9, 2024.

Xencor released a corporate overview highlighting clinical data for vudalimab in prostate cancer and progress across its bispecific antibody pipeline.

Xencor announced its fourth quarter and full year 2023 financial results, highlighting clinical progress with its T-cell engagers and vudalimab, while also reporting a workforce reduction and increased net losses.